KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) EBITDA: 2009-2024

Historic EBITDA for Rigel Pharmaceuticals (RIGL) over the last 16 years, with Dec 2024 value amounting to $24.2 million.

  • Rigel Pharmaceuticals' EBITDA rose 102.19% to $28.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $119.0 million, marking a year-over-year increase of 1151.72%. This contributed to the annual value of $24.2 million for FY2024, which is 218.06% up from last year.
  • Per Rigel Pharmaceuticals' latest filing, its EBITDA stood at $24.2 million for FY2024, which was up 218.06% from -$20.5 million recorded in FY2023.
  • In the past 5 years, Rigel Pharmaceuticals' EBITDA ranged from a high of $24.2 million in FY2024 and a low of -$55.5 million during FY2022.
  • Moreover, its 3-year median value for EBITDA was -$20.5 million (2023), whereas its average is -$17.3 million.
  • As far as peak fluctuations go, Rigel Pharmaceuticals' EBITDA tumbled by 344.54% in 2022, and later soared by 218.06% in 2024.
  • Yearly analysis of 5 years shows Rigel Pharmaceuticals' EBITDA stood at -$29.0 million in 2020, then spiked by 56.87% to -$12.5 million in 2021, then plummeted by 344.54% to -$55.5 million in 2022, then skyrocketed by 63.11% to -$20.5 million in 2023, then skyrocketed by 218.06% to $24.2 million in 2024.